INTRODUCING Guardian<sup>&trade;</sup> Connect

Wednesday, July 20, 2016 - 12:46



Improving access to better health outcomes for Australian’s with diabetes is important to us. So is reducing the cost and risk of co-morbidity. It also matters to the community and the Government which was affirmed during the 2016 Federal Election with bipartisan support for continuous glucose monitoring (CGM).

Medtronic are committed to providing CGM. Later this year our newest CGM offering Guardian Connect will be available and Australian’s with diabetes using insulin injections will be able to take out the guesswork between finger sticks.

The Guardian Connect system consists of a small wearable CGM device that takes glucose readings every five minutes (288 times a day) and sends them directly to a smartphone app. People on insulin injections can use it to check glucose levels on their mobile phones, enabling them to see highs and lows in real-time, understand the trends, and help improve their daily management of diabetes. Alerts can also be set up if glucose goes above or below preset levels, helping patients prevent or address potentially dangerous high and low glucose events. All of this information can be shared with care partners via SMS text messages and via access to the real-time CGM tracing from any web-enabled device. In addition, healthcare providers can also leverage automatic daily data uploads via CareLink Professional, Medtronic’s therapy management software.  

According to Associate Professor David O’Neal of the Department of Diabetes and Endocrinology at St Vincent’s Hospital Melbourne, “Most people with diabetes on multiple daily injections monitor their glucose levels in an ad hoc manner with finger-prick blood glucose readings. While a structured approach to blood glucose monitoring may be recommended, it does require significant effort and discomfort on the part of the patient. In many cases adherence is suboptimal.  Guardian Connect provides glucose levels in real time 24/7 and alerts the patient to glucose levels that are predicted to drift outside their target range. It also provides a more effective tool in enabling the patient and the health professional to reflect upon the impact that the patient's actions can have on their glucose levels and to devise management strategies accordingly. Our ultimate aim is to minimise the impact of diabetes on the patient's physical wellbeing and quality of life. Guardian Connect’s integration with smart phone technology is a significant step towards this goal.”

The Guardian Connect smartphone app will initially be available with iOS devices. Medtronic is working on an Android version of the Guardian Connect app as well.

Guardian Connect will be available to purchase on subscription from $9 per day later in 2016. More information will be shared in coming months.